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Paediatric and Adult Bronchiectasis: Monitoring, cross-infection, role of multi-disciplinary 
teams and self-management plans 
Abstract  
Bronchiectasis is a chronic lung disease associated with structurally abnormal bronchi; clinically 
manifested by a persistent wet/productive cough, airway infections and recurrent exacerbations. 
Early identification and treatment of acute exacerbations is an integral part of monitoring and annual 
review, in both adults and children, to minimise further damage due to infection and inflammation. 
Common modalities used to monitor disease progression include clinical signs and symptoms, 
frequency of exacerbations and/or number of hospital admissions, lung function (FEV1 %predicted), 
imaging (radiological severity of disease) and sputum microbiology (chronic infection with P. 
aeruginosa). There is good evidence that these monitoring tools can be used to accurately assess 
severity of disease and predict prognosis in terms of mortality and future hospitalisation. Other tools 
that are currently used in research settings such as health-related quality of life questionnaires, 
magnetic resonance imaging and lung clearance index can be burdensome and require additional 
expertise or resource, which limits their use in clinical practice. Studies have demonstrated that cross-
infection, especially with P. aeruginosa between patients with bronchiectasis is possible but 
infrequent. This should not limit participation of patients in group activities such as pulmonary 
rehabilitation, and simple infection control measures should be carried out to limit the risk of cross-
transmission. A multi-disciplinary approach to care which includes respiratory physicians, chest 
physiotherapists, nurse specialists and other allied health professionals are vital in providing holistic 
care.  Patient education and personalised self-management plans are also important despite limited 
evidence it improves quality of life or frequency of exacerbations.  
 
(247 words) 
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Introduction 
Bronchiectasis is a chronic suppurative lung disease characterised by abnormal dilatation of 
the bronchial tree, which is generally irreversible in adults.1 Repeated and/or chronic infection with 
recurrent respiratory exacerbations (predominantly infectious) and airway damage are hallmarks of 
the disease,2 which if left unabated leads to decline in lung function3 and respiratory failure.4 Data 
suggest that the burden of disease on secondary care services is increasing worldwide.5, 6 There is a 
pressing need to ensure accurate assessment, and optimal management, both pharmacological and 
non-pharmacological, to reduce morbidity and mortality and improve quality of life of these patients. 
This involves multiple facets and includes disease-monitoring, preventing cross-infection, 
personalised self-management plans and a multi-disciplinary approach, which is the focus of this 
review. Unless specified, bronchiectasis refers to that unrelated to cystic fibrosis (CF). 
 
Monitoring 
 Monitoring in bronchiectasis is important to identify complications, prevent cross infection 
and to aid treatment decisions so as to maintain lung function, ensure early treatment and reduce 
exacerbation frequency, and improve quality of life (QoL). These require an assessment of symptoms 
and their impact on QoL, concordance with treatment and any other concerns as an integral part of 
each review,7 with a variety of different modalities (summarised in Table 1), briefly described below. 
 
Clinical symptoms and signs 
Monitoring of clinical features related to exacerbations may prompt earlier treatment and 
reduce disease progression. Establishing the patients’ baseline (which can be altered after initial 
diagnosis and treatment) so as to enable the detection of new symptoms is clinically important and 
also used in clinical trials.8 These symptoms include changes to sputum colour and volume, dyspnoea 
and haemoptysis. Amongst adults with bronchiectasis, clinical features such dyspnoea is reported in 
over 80% of individuals9 and is associated with reduced FEV1 and radiological extent of 
bronchiectasis.10 Studies have also shown that sputum colour can predict bacterial infection11 and is 
associated with bronchial inflammation.12 However, there are limited data on changes to daily 
symptoms during the natural history of bronchiectasis and timing of the changes seen around 
exacerbations. An observational UK cohort study reported that changes to cough, breathlessness and 
sputum colour were the most prevalent symptoms at initiation of antibiotic treatment for 
exacerbations.13 There was also an association between symptom burden and fall in peak expiratory 
flow rate.13  Recently, a consensus statement for defining exacerbations in adults for clinical trials was 
developed: “a person with bronchiectasis with a deterioration in three or more of the following key 
symptoms for at least 48 hours: cough; sputum volume and/or consistency; sputum purulence; 
breathlessness and/or exercise tolerance; fatigue and/or malaise; haemoptysis AND a clinician 
determines that a change in bronchiectasis treatment is required”.14 
In children who are unable to expectorate and who may not have a continuous cough but only 
one that occurs during exacerbations or disease progression, the above symptoms are not applicable 
but instead, a change in cough quality (from dry to wet) and/or frequency/severity are markers of an 
exacerbation (when acute) or deterioration in bronchiectasis (when chronic and unaltered with 
optimal treatment).15 Other paediatric specific features include growth failure.16 
Signs of disease progression include new development of digital clubbing, chest wall abnormality, 
development of secondary cardiac disease (pulmonary hypertension signs e.g. loud P2, cardiac failure). 
In addition, monitoring of extrapulmonary of co-morbidities and/or complications should be part of a 
clinical review. There is a multitude of possible co-morbidities/complications; the more common and 
treatable ones are listed in Table 2. 
 
Health related QoL (HR-QoL) measures and disease severity 
HR-QoL measures are mainly used in research settings as they can be burdensome and difficult 
to administer in routine clinical practice. Commonly used HR-QoLs in respiratory disease include St 
George’s Respiratory Questionnaire (SGRQ), Leicester Cough Questionnaire (LCQ) and the Quality of 
life Questionnaire-Bronchiectasis (QOL-B).17 QOL-B is the first bronchiectasis-specific, HR-QoL for 
adults18, whilst SGRQ and LCQ were developed for other respiratory conditions but have been shown 
to be valid in assessing HRQoL in bronchiectasis.19, 20 To date, there have been no comparative studies 
to investigate which HRQoL questionnaire is best.  
    Given the difficulties of direct reporting for children of pre-school age, parent-proxy 
reporting is often the practice of choice. Parent-proxy cough-specific QoL (PC-QoL)21 is the tool 
commonly used in paediatric studies.22 For older children (>7 years), a child self-reporting instrument, 
chronic cough-specific QoL (CC-QoL) questionnaire 23 is a more reliable and sensitive HRQoL from the 
child’s perspective.23   
The Bronchiectasis Severity Index (BSI)24, FACED25 and e-FACED26 have been developed and 
validated in adults with bronchiectasis to define the disease severity and prognosticate outcomes 
(hospitalisation and mortality). Recently, the Bronchiectasis Aetiology Comorbidity Index (BACI) was 
developed and validated to accurately predict which patients were at higher risk of death at 5 years 
and hospitalisations.27 BACI also was able to predict frequency of exacerbations and HRQoL as 
measured by SGRQ.27 More detail on these scoring systems are set out in Review 1. None of these 
scoring systems can be validly applied in children.  
 
 
 
 
Imaging 
The sensitivity of chest radiographs (CXR) for diagnosing bronchiectasis is poor, varying 
between 37% (compared to a bronchogram28) to 87.8% (compared to high resolution computed 
tomography[HRCT]).29 It logically follows that CXR is also insensitive in monitoring disease 
progression.7 Studies amongst adults with CF demonstrated that CXR changes correlate poorly in acute 
exacerbations.30  
HRCT is currently the ‘gold standard’ for diagnosing and assessing the degree and anatomic 
extent of bronchiectasis,7, 31 although multi-detector CT (MDCT) scans are more sensitive (c.f. HRCT) 
in detecting bronchiectasis.32, 33 In a study that compared serial HRCT and functional changes in 48 
adults with bronchiectasis (median interval between scans was 28 months), 56.3% of individuals had 
HRCT features consistent with progression of disease and changes to disease severity was better 
detected on HRCT compared to FEV1.34 Radiation burden limits the use of serial chest CT scans in 
monitoring, especially in children who are approximately 10 times as sensitive to the effects of 
radiation as adults7 but as low dose CT scans are increasingly improving, this may be a future 
monitoring tool.  
The role of magnetic resonance imaging (MRI) as a non-invasive, radiation free imaging 
modality is increasingly proposed, with one study suggesting that 3-T MRI was just as effective as HRCT 
in assessing extent and severity of bronchiectasis in 30 children and 11 young adults with 
bronchiectasis.35 In young children with CF (age range 0-6 years), MRI can detect bronchiectatic 
changes from the first year of life and response to treatment of exacerbations.36 In adults, 
hyperpolarised 3He MRI reported abnormal ventilation defects in patients with bronchiectasis (n=15) 
and none in controls (n=15).37 There was also evidence of improvement in ventilation defects in 
approximately half the patients with bronchiectasis following airway clearance treatment.37 The high 
cost and expertise required to acquire and interpret the images currently limits its use in clinical 
practice. Furthermore, evidence of the role of MRI in monitoring radiological progression and 
detecting response to therapies in bronchiectasis is still lacking. 
 
Pulmonary function tests (PFTs) 
International guidelines suggest that spirometry should be performed at diagnosis7, 31 and be 
repeated at least annually in adults under secondary care follow up7 and at each review in children,31 
although spirometry can be insensitive in children.38 Airflow obstruction is the most common pattern 
seen on spirometry.39 Restrictive or a mixed patterns are also found, as is normal values (in mild 
bronchiectasis).40, 41 FEV1% predicted is the spirometric index most strongly associated with mortality24, 
25 and hospital admission.24 Adult patients with FEV1 <30% predicted had an almost 4.5 times higher 
mortality and 1.5 times higher risk of hospital at 4 years.24 Another study demonstrated that FEV1<50% 
predicted was associated with 5 times higher mortality at 5 years.25 This has resulted in FEV1 being a 
key component in bronchiectasis severity scores.24, 25 The lack of data on paediatric scoring systems 
makes it unclear if FEV1 is as useful a prognostic marker in children.  
There is little information on the role of other PFT indices in monitoring the natural history of 
bronchiectasis. One study using data from a cohort of 111 adults with bronchiectasis4 described that  
pulmonary function indices associated with mortality were higher residual volume (RV)/Total Lung 
Capacity (TLC) ratio (RR 1.03, 95%CI 1.01-1.04), lower TLC (RR 0.95, 95%CI 0.93-0.98) and lower 
transfer coefficient for the lung for carbon monoxide (Kco) (RR 0.96, 95%CI 0.94-0.98).4 A small study 
(n=27) found that mean six-minute walk distance (6MWD) had a stronger correlation with HR-QoL 
measures then spirometric indices,42 whilst a Chinese study described higher mortality in those with 
a lower 6MWD at baseline.43 Baseline 6MWD of survivors was 467.9±77.1 metres compared to 
363.7±126.7 metres in those who had died 6 years later.43 Our literature search revealed no published 
data on non-spirometric lung function indices in the paediatric population.  
There is renewed interest in the use of the Lung clearance index (LCI), from multiple breath 
washout tests, as an early marker of detecting early airway disease. While it is likely more sensitive 
than spirometry, its role is unclear, and unlikely the same as in cystic fibrosis.44, 45  
 
Lower Airway Microbiology 
 Guidelines recommend that all children and adults with bronchiectasis have an assessment7 
and surveillance31 of lower respiratory tract microbiology, although no clear guidance on its frequency 
was provided. Monitoring sputum characteristics (colour, volume) is also useful as sputum colour can 
predict bacterial infection11 and is associated with bronchial inflammation.12 In children who do not 
expectorate, microbiology monitoring poses another layer of complexity as bronchoalveolar lavage is 
required and thus this is usually not done unless there is a deterioration in the child’s clinical’s state. 
Some centre use cough swabs or induced sputum but there is controversy with regards to its accuracy, 
even in CF.46  
Microbiological surveillance is important to detect acquisition of pathogens (e.g. P.aeruginosa, 
mycobacterium, aspergillus), which can be eradicated.47, 48 These pathogens are associated with 
accelerated lung function decline49, 50 and poor outcomes.4, 51, 52 The predominant pathogen isolated 
in children is Haemophilus influenzae.53-56 In adults H. influenzae is frequently isolated, followed by P. 
aeruginosa.57, 58 Summary of a roundtable discussion amongst clinicians with an interest in 
bronchiectasis revealed varying frequencies of sputum microbiological surveillance in clinical 
practice.59 
Much can be learned from data relating to other lung diseases and some potential pitfalls 
avoided. Genetic sequencing techniques for identifying bacterial species in sputum has improved our 
understanding of lung flora and in the future, may be feasible enough to be used to assess ‘new 
infections’. For example, P. aeruginosa is more widespread in the sputum of patients admitted with 
exacerbations of chronic obstructive pulmonary disease than was previously thought and acquisition 
is associated with exacerbation.60 Individuals with CF have a tendency to pick up a strain of P. 
aeruginosa which they become chronically infected with throughout their life but which may be 
displaced by an epidemic strain.61, 62 However, there is still no consensus on how to define "chronic 
infection63 although it is important to classify patients with regards to their infection status as this 
relates to disease progression and segregation of patients based on lower airway microbiology.  
Use of other markers (e.g. anti-pseudomonal antibodies as a surrogate marker for P. 
aeruginosa) to monitor lower airway microbiology have been studied. Using a commercially available 
“anti-PA IgG” ELISA, a study of 408 individuals suggests clinical utility for initial diagnosis of chronic 
infection (n=60; sensitivity 95%, specificity 74.4%) and monitoring of treatment response to first 
isolation of P. aeruginosa (n=38).64 However there is still insufficient data to recommend its use in 
clinical practice. 
 
Exacerbations 
 Another paper in this series focuses on exacerbations; clinicians should be cognisant that 
monitoring for exacerbations and its frequency is important as exacerbations are an independent 
predictor of lung function decline49, 65 and impair QoL in adults65, 66 and children.67 Frequency of 
exacerbations is incorporated into severity scoring models (e.g. BSI24 and E-FACED68) and the ‘frequent 
exacerbator’ phenotypes (>2-3 exacerbations/year) have higher mortality.68, 69  
 
 
 
 
Cross-infection 
As patients with bronchiectasis are often chronically infected by various pathogens,70 and new 
infections can lead to persistent airway inflammation resulting in further lung damage and 
deterioration in lung function, prevention of cross-infection (transmission of pathogens between 
patients) is an increasing concern, as it also is in CF. Cross-infection can potentially occur in clinics, 
hospitals and social events (e.g. camps, schools, work).  
The follow-up of these patient groups varies worldwide, with some centres sharing clinics for 
both CF and non-CF patient groups. Recent published data from the European Bronchiectasis Registry 
suggest that across Europe 45% of adults with bronchiectasis are managed in centres with shared 
facilities with adults with CF and 10% of bronchiectasis patients are followed up in CF clinics.71 In CF, 
evidence of cross-infection with pathogens such as Methicillin-resistant Staphylococcus aureus 
(MRSA), Pseudomonas aeruginosa, Burkholderia cepacia complex and Mycobacterium abscessus72-75 
has led to guidelines recommending limiting contact between patients and setting clinics based on the 
patients’ bacteriology of clinical isolates.76  
The limited published data on cross-infection in people with bronchiectasis have, to date, 
investigated the risk of cross-infection of P. aeruginosa strains. Two United Kingdom (UK)-based 
studies and a Spanish study suggest minimal risk of cross-infections in their cohorts.77-79 One UK 
study77 investigated the risk of cross-infection amongst adults with bronchiectasis where patients 
were cared for separately and at a distance from the regional CF centre. Isolates collected from 36 
patients analysed using two genotyping methods found an absence of dominant clones of P. 
aeruginosa, leading the authors to conclude there was little evidence of cross-infection.77 More 
recently, a study of 93 adults with bronchiectasis from 16 England and Wales centres analysed 189 
isolates of P. aeruginosa from sputum samples using whole genome sequencing.78 The distribution of 
P. aeruginosa lineages found in the isolates was broadly representative of the P. aeruginosa 
population, with no data to suggest widespread transmissible strains amongst the population 
studied.78 The Spanish study used PCR fingerprinting on 64 P. aeruginosa isolates from 16 adults with 
bronchiectasis; 56% of patients harboured only one clone and 31.5% carried two clones. The genetic 
dissimilarity between the clones suggested that cross infection was unlikely to have occurred.79 
However, the possibility of the occurrence of cross transmission of P. aeruginosa amongst 
patients with bronchiectasis was raised by two other UK studies. A study using 144 isolates of P. 
aeruginosa from the sputum of 84 adults with bronchiectasis, and analysed using multiple-locus 
variable number tandem repeat typing reported that three individuals acquired epidemic strains of P. 
aeruginosa, likely from the CF population during inpatient stays.80 There was no evidence of cross-
infection of non-epidemic strains between patients with bronchiectasis.80 The second study81 of 
segregated CF and unsegregated bronchiectasis cohorts with shared facilities used sputum derived 
isolates from 46 bronchiectasis and 22 CF adults. The authors81 found that cross infection occurred in 
3 out of 46 of the unsegregated non-CF individuals but the differences in strain distribution made 
cross-transmission between patients with CF and bronchiectasis unlikely, despite sharing of facilities.81 
Within the paediatric population, there is only one published case report of a 14-year-old boy with 
bronchiectasis (secondary to chronic aspiration) infected by an epidemic strain of P. aeruginosa, 
identical to the strain which was found in four CF patients with whom he shared a room during his in-
patient stay.82   
In summary, these data depict the possibility of cross-infection with P. aeruginosa within the 
bronchiectasis population and between individuals with CF and bronchiectasis. However, such 
incidents are infrequent. Furthermore, there is insufficient evidence of new acquisition of P. 
aeruginosa as all individuals included in the studies above were already infected with P. aeruginosa. 
There are no studies examining cross-infection of micro-organisms other than P. aeruginosa in people 
with bronchiectasis and further research in this area is needed. A recent position statement by the 
European Bronchiectasis Network (EMBARC), EMBARC/ELF patient advisory group and European 
Reference Network (ERN-Lung) Bronchiectasis Network concluded that current evidence suggests 
cross-infection is uncommon83 and the benefits of group activities such as pulmonary rehabilitation84 
outweigh any theoretical risk of cross-transmission of pathogens.83 
While much may be learned and applied from CF-based studies, the cystic fibrosis 
transmembrane receptor (CFTR) dysfunction in CF leads to a fundamentally different microbiological 
niche85 compared to non-CF bronchiectasis for a number of reasons such as the different sputum 
composition, increased chloride and DNA levels and reduced airway fluid glutathione, and neutrophil 
dysfunction contribute to an environment with different selection pressures and thus different traits 
in the bacterial populations.86 However, the serious nature of the consequences and robust evidence 
of global transmission of epidemic strains of P. aeruginosa between individuals with CF87 makes the 
authors loathe to ignore simple infection control measures to reduce cross-infection. Use of face 
masks at appropriate times greatly reduces the risk of transmission between individuals88 in clinical 
settings and should be adopted where practicable. 
 
 
Role of the Multi-disciplinary team (MDT) 
Multidisciplinary care is defined as when healthcare professionals from across disciplines work 
together to provide comprehensive care aiming to meet the needs of the patient.89 Providing holistic 
care for patients with bronchiectasis to control symptoms, reduce exacerbations, preserve lung 
function and maintain quality of life requires input from all members of the multi-disciplinary team. 
Good practice guidelines recommend that as a minimum, patients be managed by a respiratory 
physiotherapist and nurse specialist alongside a chest physician.7 There are no published data 
investigating the role of MDT care in patients with bronchiectasis, particularly with regards to cost-
effectiveness. Evidence behind guidelines for MDT care in bronchiectasis is extrapolated from COPD. 
A Cochrane review found that MDT approach to patients with COPD improved not just exercise 
tolerance and quality of life, but also hospital admissions due to exacerbations and length of stay in 
hospital.90 There was however, no effect on mortality.90 We also found no information available on 
the impact of telemedicine in the management of patients with bronchiectasis.  Below we discuss 
aspects of MDT care with the largest evidence base.  
 
Chest physiotherapists and pulmonary rehabilitation  
Airway clearance techniques are widely used in treating patients with bronchiectasis, as 
discussed in another paper in this series. There is wide variety of techniques that are age, preference 
and co-morbidity dependent- thus specialised chest physiotherapists are an essential team member. 
Chest physiotherapists are also usually the leaders of pulmonary rehabilitation.  
 
Nutritionists  
There are limited studies on anthropological measurements, assessment of macro- and micro-
nutrition or nutritional supplementation in individuals with bronchiectasis. Nevertheless, nutritional 
issues may occur especially in those with severe disease and thus, nutritionists are part of the MDT. 
An Australian study retrospectively reviewed longitudinal data from 52 children with bronchiectasis 
over 3-5 years and described improvements in BMI z-scores per annum over 3 years, but no further 
change at five year follow up (n=25).65 Similar to the findings of a London cohort91, children with worse 
spirometry (FEV1<80% predicted) at baseline were associated with a lower BMI.65 Amongst 98 Turkish 
adults with bronchiectasis had a mean BMI of 27.62 (SD 6.36), and a lower BMI was strongly associated 
with mortality.92 However, a Spanish study of 76 adults reported no difference in mean BMI between 
patients who had rapid decline in lung function compared to those who did not.49  
 
 
 
Nurse specialist and nurse-led care 
 Within a MDT, the nurse specialist is often the first point of contact for patients. In most teams, 
the nurse specialist has the key role of an integrated approach to chronic disease management e.g. 
COPD and diabetes, as well as leading health education. In some centres, a nurse-led care approach is 
used. However, a recent systematic review evaluating the safety and efficacy of nurse-led care 
amongst adults with bronchiectasis included only one RCT,93 a UK study crossover trial with 80 adults 
with bronchiectasis who were treated for 12 months by a specialist nurse or doctor, who then crossed 
over to the other clinician for the next 12 months.94 There was no difference in mean FEV1 between 
the groups and no differences in other clinical outcomes or HR-QoL measures, but patients in the 
nurse-led care group had higher hospital admissions.94 Further analyses by the authors of the 
systematic review demonstrated no difference in the number of exacerbations requiring treatment 
with antibiotics.93 Although initially the nurse-led care group had higher treatment costs, by the end 
of the trial, these were equitable.93, 94  
Our literature search also revealed a non-randomised pilot study of specialist nurse-led 
cognitive behavioural therapy (CBT) in adult patients with longstanding and severe bronchiectasis. 95 
There were no differences in levels of anxiety and depression between the groups.95 There was a 
marked difference in SGRQ scores between the groups at the baseline; likely due to selection bias as 
“sicker” patients chose to be in the control group. The difference in SGRQ scores between the groups 
remained at the end of the study, but was lower in the CBT group. 95 The shuttle test distance in the 
CBT group was higher both pre-and post -intervention. 95 This study raises the possibility of CBT playing 
a role in improving overall health in adults with bronchiectasis, but severe limitations of its design 
mean more robust clinical trials need to be carried out before firm conclusions can be drawn.  
 
 
Self-management plans 
Educating individuals with bronchiectasis, including explanation of their condition, how to 
recognise infective exacerbations and the importance of treatment, as well as a personalised 
management plan with approaches and options to treatment is recommended.7, 96 Qualitative studies 
have highlighted that patients felt that information available was lacking, there was a need for 
accessible information outside the specialist clinic setting and increasing resources could equip 
patients to manage their disease more effectively.97, 98 A study using focus groups found that although 
patients had conflicting views on the meaning of self-management, most were comfortable with the 
opportunity to self-manage their condition, especially if it helps avoid admission to hospital.99 
A systematic review assessed the efficacy, cost-effectiveness and adverse effects in self-
management interventions amongst people with bronchiectasis that included two adult-based 
RCTs.100 One was a proof of concept RCT comparing usual care with an expert patient programme 
described no differences in SGRQ total scores between the groups post-intervention, at three or six 
months after intervention.101 The other RCT of early rehabilitation, self-management and usual care 
(six weeks of intervention) compared to usual care in adults with chronic respiratory disease, which 
included 20 individuals with bronchiectasis.102 Amongst the subset of participants with 
bronchiectasis102 there was a trend in improvement in mean SGRQ scores for both groups, but this did 
not meet statistical significance at six weeks, 3 or 12 months follow up.100 Although the mean 
difference in SGRQ scores between the groups exceeded the minimum clinical important difference103 
the lack of power from the small sample size (n=20) means conclusions are unable to be drawn.100 The 
authors of the systematic review concluded that there is insufficient evidence to determine if self-
management interventions impact HR-QoL or exacerbations.100  
 
 
Conclusion 
In summary, current evidence suggests a low risk of cross-infection of P. aeruginosa in 
bronchiectasis. At present the benefits of group participation activities such as pulmonary 
rehabilitation and structured exercise programmes likely outweigh the risks of possible cross-
transmission of pathogens, but more evidence is required. Further research and consistent 
terminology surrounding infection status, particularly with regards to chronic P. aeruginosa infection 
are also lacking. A validated and universally adopted classification of infections will help guide 
treatment and prognosis in and individual clinical setting, and facilitate research into future therapies, 
clinical governance and quality assurance.  
There are a wide range of modalities available for disease monitoring, but the cost and 
expertise involved in some of these tools may limit their use as part of routine care. There is also a 
lack of clarity on optimal frequency of monitoring and the role of telemedicine in the follow-up of 
stable patients. Despite multi-disciplinary care and self-management being part of good practice 
guidelines, there is a paucity of evidence. Until more evidence is obtained in the neglected field of 
bronchiectasis, practice should be based on national guidelines.  
 
 
 
 
 
 
 
 
Table 1: Modalities used for monitoring patients with bronchiectasis. 
Test for 
monitoring 
Major Findings Advantage Limitation Evidence  
    Children Adults 
Symptoms 
and signs 
Increased 
sputum volume, 
change in 
sputum 
purulence, chest 
pain, dyspnoea 
Easy to 
recognise 
Insensitive, 
dependent of 
patients’ recall  
Change of cough 
characteristics 
with 
exacerbations, 
associations of 
symptoms and 
signs with other 
markers of 
bronchiectasis 
severity.104, 105 
Sputum colour 
can predict 
bacterial 
infection11 and is 
associated with 
bronchial 
inflammation.12 
Quality of life 
measures 
St George’s 
Respiratory 
Questionnaire 
(SGRQ),19 
Leicester Cough 
Questionnaire 
(LCQ)20 have 
been validated 
in patients with 
bronchiectasis. 
Quality of life 
bronchiectasis 
(QOL-B) is a 
disease specific 
questionnaire.18 
Widely 
available 
Not routinely 
used in clinical 
practice 
Parent-proxy 
cough-specific 
QoL (PC-QoL) 
used in pre-school 
children.21 
Chronic cough-
specific QoL (CC-
QoL) 
questionnaire for 
older children 
able to self-
report.23 
Relationship 
between QoL 
measures and 
other 
bronchiectasis 
markers of 
severity. 22 
A systematic 
review found 
currently used 
HRQoL measures 
valid and reliable 
in 
bronchiectasis.17 
Spirometry Decrease in FEV1 Widely 
available, 
easy to use 
in follow 
up 
In mild 
disease, 
spirometry 
values are 
normal. 
Can be difficult 
to obtain from 
young children 
(aged < 5 
years) 
Several cohort 
studies comparing 
chest CT scan with 
spirometry38, 91 
and/or 
description of 
lung function in 
cohorts 
FEV1 associated 
with disease 
severity as 
measured by BSI 
24 and FACED.25 
Transfer 
coefficient of 
the lung for 
carbon 
monoxide 
(Kco) 
Reduced Kco Widely 
used in 
clinical 
practice 
Difficult 
obtaining 
reproducible 
measurements 
due to cough 
No data available Lower Kco was 
associated with a 
slight reduction in 
mortality (RR 
0.96, 95% CI 0.94-
0.98)4 
Total lung 
capacity (TLC) 
Reduced TLC Widely 
used in 
clinical 
practice 
Different 
methods in 
measuring TLC 
No evidence Lower TLC found 
to be associated 
with slightly 
reduced risk of 
death (RR 0.95, 
95% CI 0.93-
0.98)4 
Six-minute 
walk test 
(6MWT) 
Reduced 
distance usually 
seen at six 
minutes 
(6MWD) 
Good 
measure of 
functional 
status in 
chronic 
respiratory 
disease 
Can be 
influenced by 
external 
factors e.g. 
skeletal muscle 
dysfunction 
No evidence Moderate 
correlation 
between 6MWD 
and FEV1 and FVC 
percent 
predicted. 42 
No association 
with HRCT 
severity of 
bronchiectasis. 42 
Strongly 
associated with 
HRQoL measures. 
19 Shorter 6MWD 
associated with 
higher mortality. 
43 
Lung 
clearance 
Index (LCI) 
Higher values 
seen in patients 
with 
bronchiectasis 
Non-
invasive, 
repeatable. 
Time intensive 
to obtain, 
limited 
availability, 
research tool 
No reliable data in 
bronchiectasis 
unrelated to CF. 
LCI may be more 
sensitive than 
spirometry in 
children with 
CF.106  
Inconsistent 
results.44, 45 
However, maybe 
more sensitive 
measure 
compared to 
FEV1. 107 
Associated with 
spirometric 
airflow 
obstruction.108 
Chest 
radiograph 
Increased linear 
markings, 
crowding of 
bronchi, mucous 
plugs, bronchial 
wall thickening, 
tram tracking 
Low cost, 
highly 
available, 
low 
radiation 
dose 
Can be normal CXR is of little 
diagnostic value 
in children109 
Poor correlation 
between infective 
exacerbations 
and radiographic 
changes.30 
High 
resolution 
computed 
tomography 
(HRCT) 
Various 
bronchiectasis 
radiology score 
e.g. Bhalla, 
Webb reflecting 
increasing 
severity of 
bronchial wall 
dilatation, 
bronchial wall 
thickening, 
signet ring. 
Change from 
cylindrical to 
varicose to cystic 
bronchiectasis 
Current 
gold 
standard 
for 
diagnosis 
Radiation 
burden limits 
the use in 
monitoring 
radiological 
progression 
A broncho-arterial 
ratio > 0.8 is 
considered 
diagnostic of 
bronchiectasis.110 
Relationship 
between 
radiological scores 
and other 
markers of 
bronchiectasis 
severity.38, 111  
Relationship 
between 
radiological 
scores and other 
markers of 
bronchiectasis 
severity.112 
Magnetic 
Resonance 
Imaging (MRI) 
Ventilation 
defect percent 
Radiation 
free 
Time and cost 
associated 
with image 
Requires 
validation for 
In patients with 
CF, changes seen 
on  3He MRI 
in areas of 
bronchiectasis 
imaging 
modality 
acquisition 
may limit the 
use to tertiary 
centres 
diagnosis and 
monitoring 
strongly 
correlated with 
abnormalities 
seen on HRCT and 
spirometry.113  A 
small study 
(n=15) in people 
with 
bronchiectasis 
showed that 
structure-
function 
abnormalities 
seen on 
hyperpolarised 
3He MRI 
correlated well 
with CT 
changes.37 
Sputum 
microbiology 
Haemophilus 
influenzae is 
common in 
children 53-56. 
In adults H. 
influenzae and 
P.aeruginosa are 
commonly 
isolated.57 58 
Widely 
used in 
clinical 
practice 
Multiple 
bacterial 
species can be 
isolated in a 
single sputum 
sample. 
Difficulty in 
obtaining 
samples in pre-
school children 
Limited data 
describing lower 
microbiology in 
children with 
bronchiectasis.    
P. aeruginosa is 
uncommon in 
children with 
bronchiectasis.54 
P. aeruginosa 
strongly 
associated with 
lung function 
decline,49 disease 
severity 24, 25 and 
mortality.4 
Exacerbations Change in 
sputum volume 
and/or colour, 
increasing 
breathlessness 
and/or reduced 
exercise 
tolerance, 
lethargy, 
malaise, 
haemoptysis. 
International 
guidelines long 
term antibiotics 
(inhaled or oral) 
if a patient has 3 
or more 
exacerbations a 
year.31, 84, 114 
 Varying 
definitions of 
exacerbation 
have been 
used in 
studies. 
Wet cough and 
cough severity 
were the best 
predictors of 
exacerbations in 
children.15 
Respiratory 
viruses were 
detected in 
almost 50% of 
exacerbations in 
children. 115 
Frequency of 
exacerbations 
requiring 
hospitalisation 
was associated 
with rapid decline 
in lung function.65 
P. aeruginosa is 
associated with 
more frequent 
exacerbations.116 
Frequent 
exacerbations are 
associated with 
higher disease 
severity and 
mortality.68, 69 
  
Table 2: Common co-morbidities/complication in bronchiectasis 
Co-morbidities/complications as part 
of treatable traits 47, 48 
Main symptoms and signs 
Asthma-like disease117 Breathlessness, wheeze, chest tightness, cough (especially at 
night), diurnal variation in peak flow recording. 
Chronic obstructive pulmonary 
disease118 
Productive cough, breathlessness (especially on exertion), 
wheeze, hyperinflation, air trapping. Fixed airflow obstruction on 
spirometry 
Gastro-oesophageal reflux 119 Heartburn, epigastric pain, chest discomfort, regurgitation 
Sinusitis120 Nasal obstruction/congestion, anterior/posterior rhinorrhoea, 
anosmia, headache, facial pain/pressure. Nasal polyps, 
mucopurulent discharge, oedematous middle meatus 
Ischaemic heart disease121 Central chest pain (on exertion or at rest) radiating to the jaw 
and/or left arm, shortness of breath 
Anxiety and/or depression122 Feelings of apprehension or dread, poor concentration, insomnia 
and/or sleep disturbance, anhedonia, low mood, poor appetite, 
lethargy 
Hypoxaemia Breathlessness on exertion and/or at rest, lethargy, tachycardia, 
confusion, desaturation on exertion, peripheral cyanosis 
Pulmonary hypertension123 Dyspnoea on exertion and/or at rest, syncope, chest pain, fatigue, 
peripheral oedema, peripheral or central cyanosis 
Urinary incontinence124, 125 Stress incontinence (leaking urine during extra sudden pressure 
e.g. coughing, laughing, exercise), urge incontinence, overflow 
incontinence  
Dental disease126 Halitosis, red, swollen, bleeding, receding gums, sensitive teeth 
Sleep disordered breathing127 Unrefreshed sleep, excessive daytime somnolence, early morning 
headaches, fatigue, lethargy, nocturia, weight gain 
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